Buckhill Capital Invests in Cadence Health’s Series B Round

Originally published on Issue Wire

Buckhill Capital LP invested in Cadence Health, a women’s health care company that is making a cost-effective birth control pill to be available over the counter.  Buckhill invested in the Series B round with other investors, including Gratitude Railroad, Disney Family Office, Tara Health, Templeton World Charities, Educational Foundation of America, The Husseini Group LLC, NJF Capital, and Impact Assets.

Nearly half of all pregnancies in the United States are unintended with around 2,800,000 unplanned pregnancies annually, a major limiting factor for women and their communities.  Pregnant teenagers are unlikely to complete high school and likely to be severely financially challenged.

“By making two of the most popular pills available over-the-counter, Cadence Health could dramatically improve the health and welfare of both women and their children.  Buckhill invested in Cadence because it could have huge social and environmental impacts in communities around the globe,” said Henrik Jones, a partner at Buckhill.

The United States is behind the curve in making safe contraceptives easily accessible to the people who need it most.  The pill is available in many other countries as an over-the-counter drug, increasing access and affordability.  It is the most popular form of contraception in the US but is only available by prescription, a barrier for especially young women. 

About Cadence Health: Founded by Dr. Nap Hosang and Samantha Miller, Cadence is on a mission to liberate the pill and bring women’s birth control over the counter.  Cadence has acquired rights to two of the most popular formulations of the pill and is going through FDA approval to sell over the counter (OTC) for the first time ever.